Jump to content
Pharmacy Wolverine

A street-wall research wall on the Wolverine peptide blend — BPC-157 and TB-500 tagged up as what the literature on each constituent actually shows, and where compounded access and the FDA 503A line really stand.

SOURCE LIST · BPC-157 + TB-500

BPC-157 TB-500 references, with each fact tied to a source

The list holds studies on each substance, FDA pages on pharmacy mixing, and the world sport ban.

Return to the study notesRead the FDA status

What each source can tell you

Each substance was first made for its own line of research. Labs then tested them one at a time. You can use this list to find those papers. Each numbered mark points to one item below. The BPC-157 TB-500 items include first studies and later reviews. FDA pages support facts about pharmacy mixing. The World Anti-Doping Agency list supports the sport rules.

Items 1-12 cover the two substances. Items 13-16 explain Wolverine rules and the FDA rule for a local pharmacy making mixed medicine for a specific patient. That federal rule is often called 503A. When a study used rats, mice, or cells, the entry says so. Animal results can't establish a benefit from the blend in people.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  6. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
  7. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  8. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  9. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025;17(1):119. ↗
  10. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina (Kaunas). 2025;61(2):291. ↗
  11. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. ↗
  12. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. ↗
  13. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 entries for BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; list update effective September 29, 2023). ↗
  14. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (BPC-157 and TB-500 listed as bulk drug substances being considered for inclusion on the 503A Bulks List). ↗
  15. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 / Category 2 framework and the 503A/503B compounding pathway). ↗
  16. World Anti-Doping Agency. The Prohibited List (BPC-157 under category S0 Non-Approved Substances; TB-500 / thymosin beta-4 under prohibited peptide and tissue-repair categories). ↗
  17. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003. ↗
  18. Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. ↗
  19. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. ↗
  20. et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021. ↗